Surrey Heartlands

Joint Formulary & PAD

Sacubitril/valsartan - Heart failure

You are here : Home > Formulary Search > Sacubitril/valsartan - Heart failure

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
 

Status 2

Non Formulary
Formulations :
  • Granules
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NFD1
Restrictions / Comments :
Important

Only licensed for use in children.

Documentation

Shared Care
RSCH - Sacubitril valsartan in chronic heart failure - Amber Shared Care - Sep 2016
Shared Care
Sacubitril Valsartan in chronic Heart Failure - Amber shared-care - Sep 2016
Policy Statement
Sacubitril_valsartan - Policy statement APC 2016-2016 Jun2016 .pdf
Webpage
NICE TA388 - Sacubitril Valsartan in Chronic Heart Failure
Miscellaneous
Sacubitril valsartan in chronic heart failure - Briefing Paper - June 2016

PAD Profile

ChemicalSubstance :
Sacubitril/valsartan
Indication :
Heart failure
Group Name :
Keywords :
Sacubitril, CHF, valsartan, neprilysin inhibitor, angiotensin receptor antagonist
Brand Names Include :
Entresto
Important Information :
Do not co-administer with an ACEi or ARB due to risk of angioedema.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Heart failure
Supporting Documents :
5
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Sacubitril/valsartan is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Heart failure.

Committee Recommendations (1)

01 Jun 16 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Sacubitril/Valsartan (Entresto®) for treating symptomatic chronic heart failure with reduced ejection fraction in line with NICE guidance (TA388 – April 2016) and will be considered as AMBER on the traffic light system. CCGs in conjunction with local Acute Trusts will make local implementation plans as required